このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

OED、DCIS、およびLCISにおけるCAN1012。

2026年9月21日 更新者:Providence Health & Services

口腔上皮異形成、乳管内癌、および小葉内癌における局所TLR7作動薬CAN1012を評価する第I相/Ib相試験

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

調査の概要

状態

募集

介入・治療

詳細な説明

This is not a dose finding study, and therefore patients may be enrolled to any of the four arms in any order, based on clinical considerations (e.g. OR scheduling). No arm, per specific disease type, may expand beyond the first 3 patients, until 30-day post-op safety evaluation has been completed. Study analysis is planned after a single dose of intralesional CAN1012.

The primary objective of this trial is to examine the safety of CAN1012 delivered by intralesional injection ahead of planned surgical resection. The study will be stopped early for patient safety according to stopping rules below. The sample size for the study is not based on any statistical assumptions. The number of subjects is based on the number of cohorts tested and the size of each cohort.

The Safety Analysis Set will consist of all subjects who receive at least one dose of study treatment. The Safety Analysis Set will be used for safety analyses.

The Intent-to-treat (ITT) Analysis Set will consist of all subjects who receive at least one dose of study treatment and have at least one post-Baseline assessment of tumor response.

The disposition of subjects will be summarized by presenting the number of subjects enrolled, the number and percentage of subjects in each analysis population, the number for whom the study drug was discontinued with the reasons for discontinuation, and the number of subjects who discontinued participation in the study with the reason(s) for withdrawal.

研究の種類

介入

入学 (推定)

24

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Oregon
      • Portland、Oregon、アメリカ、97213
        • 募集
        • Providence Portland Cancer Institute - Franz Clinic
        • 副調査官:
          • Rom Leidner, MD
        • 副調査官:
          • Matthew Taylor, MD
        • 副調査官:
          • David Page, MD
        • 副調査官:
          • Alison Conlin, MD
        • 副調査官:
          • Roxanne Griswold, NP
        • 副調査官:
          • Rui Li, MD, PhD
        • 副調査官:
          • RaYoung Chung, NP
        • 副調査官:
          • Amy Hartman, NP
        • 副調査官:
          • Molly Davis, NP
        • 副調査官:
          • Brendan Curti, MD
        • 副調査官:
          • Rachel Sanborn, MD
        • コンタクト:
        • 主任研究者:
          • Sasha Stanton, MD, PhD
        • 副調査官:
          • Mary Martel, NP
        • 副調査官:
          • Jamie Martinez, NP
        • 副調査官:
          • Binbin Zheng, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female patients with DCIS or LCIS found on core biopsy.

  2. Tumor types allowed:

    Biopsy-identified DCIS or LCIS comprising a single lesion ≥ 1 cm and ≤ 5 cm in size by imaging (mammogram or MRI or ultrasound (US)) without evidence of invasive disease on the biopsy and US negative for suspicious ipsilateral lymph nodes.

  3. Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.

  5. Laboratory values within 72 hours of Day 0:

    1. WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
    2. Hgb ≥ 10 g/dL
    3. Platelets ≥ 100,000 K/µL
    4. Creatinine Clearance (using Cockcroft-Gault) ≥ 60.
    5. AST/ALT ≤ 2.5 x ULN
    6. Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
    7. Negative pregnancy test for people of childbearing potential (bHCG urine or serum)
  6. Patients and their partners who are capable of conceiving must agree to use effective methods of contraception (non-hormonal only) during the course of treatment and for 165 days after last dose of CAN1012.

Exclusion Criteria:

  1. Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
  2. Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
  3. Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
  4. History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/hyperthyroidism are not exclusionary.
  5. Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
  6. Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
  7. Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
  8. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known history of Hepatitis C virus (defined as HCV RNA) infection. Testing for Hepatitis B and Hepatitis C is not required unless mandated by local health authority.
  9. Has a baseline electrocardiogram (ECG) with a prolonged QTc interval > 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
  10. Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm A: Day 2-3

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 2-3.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

実験的:Arm B: Day 5-7

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 5-7.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

実験的:Arm C: Day 9-11

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 9-11.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

実験的:Arm D: Day 13-15

Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 13-15.

CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety of CAN1012
時間枠:Post-operative follow-up visit (30 days after surgery)

Safety will be measured by demonstrating that there is a less than 33% rate of delayed surgery attributable to the study treatment.

Post-operative follow-up visit (30 days after surgery)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Sasha Stanton, MD, PhD、Providence Health & Services

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月16日

一次修了 (推定)

2030年5月1日

研究の完了 (推定)

2035年5月1日

試験登録日

最初に提出

2026年2月3日

QC基準を満たした最初の提出物

2026年2月10日

最初の投稿 (実際)

2026年2月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する